Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Analysts Set New Price Targets
Separately, HC Wainwright upped their price objective on shares of Revance Therapeutics from $20.00 to $25.00 in a research report on Wednesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Revance Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $25.00.
Revance Therapeutics Trading Down 0.6 %
Shares of Revance Therapeutics stock opened at $21.44 on Friday. Revance Therapeutics has a 52-week low of $11.27 and a 52-week high of $30.00. The firm has a market capitalization of $1.56 billion, a PE ratio of -5.57 and a beta of 1.03. The company has a debt-to-equity ratio of 14.80, a current ratio of 4.01 and a quick ratio of 3.87. The company's fifty day moving average price is $15.13 and its two-hundred day moving average price is $15.50.
Revance Therapeutics (NASDAQ:RVNC - Get Rating) last issued its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.03). Revance Therapeutics had a negative net margin of 265.04% and a negative return on equity of 368.74%. The business had revenue of $25.26 million for the quarter, compared to analyst estimates of $23.55 million. On average, analysts expect that Revance Therapeutics will post -3.97 EPS for the current year.